Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Genesee & Wyoming Reports Results for the First Quarter of 2019

Published

on

Reading Time: 13 minutes

DARIEN, Conn.–(BUSINESS WIRE)–Genesee & Wyoming Inc. (G&W) (NYSE:GWR)

First Quarter 2019 Consolidated Highlights Compared with First
Quarter 2018

  • Operating revenues decreased 2.9% to $558.1 million from $574.7
    million.
  • Reported operating income decreased 8.3% to $79.7 million; Adjusted
    operating income increased 0.5% to $87.8 million despite negative
    effects from severe winter weather and flooding in North America.(1)
  • Reported diluted earnings per common share (EPS) decreased 42.9% to
    $0.68 with 57.1 million weighted average shares outstanding, compared
    with reported diluted EPS in the first quarter of 2018 of $1.19 with
    62.9 million weighted average shares outstanding; Adjusted diluted EPS
    increased 11.4% to $0.78.(1)
  • Reported net income and diluted EPS for the first quarter of 2019
    included $5.4 million, or $0.10 per share, of restructuring and
    related costs. Reported net income and diluted EPS for the first
    quarter of 2018 included a $31.6 million, or $0.50 per share, income
    tax benefit associated with the U.S. Short Line Tax Credit for fiscal
    year 2017 that was enacted retroactively in February 2018.

Company Comments

Jack Hellmann, Chairman and Chief Executive Officer of G&W, commented,
“In the first quarter of 2019, our adjusted diluted EPS increased over
11%, despite severe winter weather and flooding in North America that
impeded shipments from connecting Class I railroads to our Midwest and
Canada regions. These weather impacts resulted in a $0.09, or 10%,
reduction in diluted EPS compared with our first quarter guidance. We
expect to recover a portion of the winter-affected traffic in the coming
months, our outlook for North American rail shipments remains positive
and our 2019 annual guidance remains unchanged.”

“In the first quarter of 2019, we implemented cost reduction initiatives
in each of our three geographic segments. In North America, we
consolidated our Central Region into our Midwest and Southern regions.
In the U.K./Europe, we continued to make reductions in our overhead cost
structure and to invest in technology, and in Australia, we streamlined
rail operations concurrent with the termination of grain operations on
the Eyre Peninsula narrow gauge network.”

“Finally, in the first quarter of 2019, we evaluated several potential
acquisitions and investments. And in March, we signed two long-term
leases of short line railroads in Indiana that create a contiguous
400-mile, four-railroad footprint (CERA-TPW-TZPR-IMRR) within our
Midwest Region, spanning from Eastern Indiana to Western Illinois with
connections to six Class I railroads.”

First Quarter Segment Highlights

  • North America: Operating revenues from G&W’s North American Operations
    increased 2.1% to $332.4 million from $325.6 million. Revenue for the
    first quarter of 2018 included $5.5 million of revenues from leased
    railroads in Canada, for which the leases expired at the end of 2018.
    Reported operating income from G&W’s North American Operations, which
    was negatively impacted by severe winter weather in the United States
    and Canada and flooding in the Midwestern United States, decreased
    5.3% to $69.3 million; Adjusted operating income from G&W’s North
    American Operations decreased 4.2% to $70.3 million.(1)
  • Australia: Operating revenues from G&W’s 51.1% owned Australian
    Operations decreased 13.0% to $65.1 million from $74.8 million.
    Reported operating income from G&W’s Australian Operations decreased
    21.7% to $12.5 million; Adjusted operating income from G&W’s
    Australian Operations decreased 11.9% to $14.1 million. Operating
    income from G&W’s Australian Operations were negatively impacted by
    $1.5 million from foreign currency depreciation and $1.5 million from
    drought conditions in South Australia and New South Wales, which were
    partially offset by a decrease in expenses.(1)
  • U.K./Europe: Operating revenues from G&W’s U.K./European Operations
    decreased 7.8% to $160.5 million from $174.2 million. Revenues for the
    first quarter of 2018 included $14.7 million of revenues from G&W’s
    former Continental Europe intermodal business, ERS Railways B.V.
    (ERS), which was sold in June 2018. Reported operating loss from G&W’s
    U.K./European Operations remained relatively flat at $2.1 million.
    Adjusted operating income from G&W’s U.K./European Operations
    increased to $3.4 million from an adjusted operating loss of $2.0
    million in 2018.(1)

Financial Results

G&W’s operating revenues decreased $16.6 million, or 2.9%, to $558.1
million in the first quarter of 2019, compared with $574.7 million in
the first quarter of 2018. G&W’s operating income in the first quarter
of 2019 was $79.7 million, compared with $86.9 million in the first
quarter of 2018. Excluding certain items affecting comparability between
periods discussed below, G&W’s adjusted operating income in the first
quarter of 2019 was $87.8 million, compared with $87.4 million in the
first quarter of 2018.(1)

G&W’s provision for income taxes in the first quarter of 2019 was $14.3
million, while the benefit from income taxes for the first quarter of
2018 was $15.9 million. G&W’s effective tax rate for the first quarter
of 2019 was 26.9%, compared with 26.2% in the first quarter of 2018,
excluding the $31.6 million income tax benefit from the retroactive
extension of the of the U.S. Short Line Tax Credit for fiscal year 2017
that was enacted in February 2018.

Reported net income attributable to G&W in the first quarter of 2019 was
$38.7 million, compared with reported net income attributable to G&W of
$75.1 million in the first quarter of 2018. Excluding the net impact of
certain items affecting comparability between periods discussed below,
G&W’s adjusted net income attributable to G&W in the first quarter of
2019 was $44.4 million, compared with $43.8 million in the first quarter
of 2018.(1)

G&W’s reported diluted EPS in the first quarter of 2019 were $0.68 with
57.1 million weighted average shares outstanding, compared with reported
diluted EPS in the first quarter of 2018 of $1.19 with 62.9 million
weighted average shares outstanding. G&W’s adjusted diluted EPS in the
first quarter of 2019 were $0.78 with 57.1 million weighted average
shares outstanding, compared with adjusted diluted EPS in the first
quarter of 2018 of $0.70 with 62.9 million weighted average shares
outstanding.(1)

Items Affecting Comparability

In the first quarter of 2019 and 2018, G&W’s results included certain
items affecting comparability between the periods that are set forth in
the following table (in millions, except per share amounts):

               

Income/(Loss)
Before Income
Taxes
Impact

After-Tax Net
Income/(Loss)
Attributable
to

G&W Impact

Diluted EPS
Impact

Three Months Ended March 31, 2019

Corporate development and related costs $ (0.4 ) $ (0.3 ) $ (0.01 )
Restructuring and related costs $ (7.6 ) $ (5.4 ) $ (0.10 )
 

Three Months Ended March 31, 2018

Corporate development and related costs $ (0.2 ) $ (0.1 ) $
Restructuring and related costs $ (0.3 ) $ (0.2 ) $
2017 Short Line Tax Credit $ $ 31.6 $ 0.50
 

In the first quarter of 2019, G&W’s results included restructuring and
related costs of $7.6 million, primarily driven by our optimization
activities in the U.K., and corporate development and related costs of
$0.4 million.

In the first quarter of 2018, G&W’s results included a $31.6 million
income tax benefit associated with the U.S. Short Line Tax Credit for
fiscal year 2017 that was enacted in February 2018.

First Quarter Results by Segment

Operating revenues from G&W’s North American Operations increased $6.8
million, or 2.1%, to $332.4 million in the first quarter of 2019,
compared with $325.6 million in the first quarter of 2018. Excluding
$5.5 million of revenues from lease expirations in Canada for the first
quarter of 2018 and a $1.1 million decrease due to the impact of foreign
currency depreciation, North American Operations same railroad revenues
increased $13.3 million, or 4.2%, primarily due to increases in freight
and freight-related revenues.

G&W’s North American Operations were negatively impacted by extreme
winter weather in the United States and Canada and flooding in the
Midwestern United States. Operating income from G&W’s North American
Operations was $69.3 million in the first quarter of 2019, compared with
$73.2 million in the first quarter of 2018. The operating ratio for
North American Operations was 79.1% in the first quarter of 2019,
compared with 77.5% in the first quarter of 2018. Adjusted operating
income from G&W’s North American Operations in the first quarter of 2019
was $70.3 million, compared with $73.4 million in the first quarter of
2018. The adjusted operating ratio for North American Operations was
78.9% in the first quarter of 2019, compared with an adjusted operating
ratio of 77.5% in the first quarter of 2018.(1)

Operating revenues from G&W’s Australian Operations decreased $9.7
million, or 13.0%, to $65.1 million in the first quarter of 2019,
compared with $74.8 million in the first quarter of 2018. Excluding a
$7.0 million decrease due to the impact of foreign currency
depreciation, Australian Operations revenues decreased $2.7 million, or
4.0%, primarily due to decreases in drought impacted agricultural
products freight revenues and freight-related revenues.(2)

G&W’s Australian Operations had operating income of $12.5 million in the
first quarter of 2019, compared with $16.0 million in the first quarter
of 2018. The operating ratio for Australian Operations was 80.8% in the
first quarter of 2019, compared with 78.7% in the first quarter of 2018.
Adjusted operating income from G&W’s Australian Operations was $14.1
million in the first quarter of 2019, compared with $16.0 million in the
first quarter of 2018. The adjusted operating ratio for Australian
Operations was 78.4% in the first quarter of 2019, compared with 78.6%
in the first quarter of 2018. Operating income from G&W’s Australian
Operations was negatively impacted by $1.5 million from foreign currency
depreciation and $1.5 million from drought conditions in South Australia
and New South Wales, which were partially offset by a decrease in
expenses.(1)

Operating revenues from G&W’s U.K./European Operations decreased $13.7
million, or 7.8%, to $160.5 million in the first quarter of 2019,
compared with $174.2 million in the first quarter of 2018. Excluding
$14.7 million of revenues from G&W’s divested ERS operations for the
first quarter of 2018 and an $11.0 million decrease due to the impact of
foreign currency depreciation, U.K./European Operations same railroad
revenues increased $12.1 million, or 8.1%, primarily due to increases in
U.K. intermodal freight-related and freight revenues.(2)

G&W’s U.K./European Operations had an operating loss of $2.1 million in
the first quarter of 2019, compared with and operating loss of $2.2
million in the first quarter of 2018, which included operating income of
$0.5 million from ERS. The operating ratio for G&W’s U.K./European
Operations of 101.3% in the first quarter of 2019 remained unchanged
compared with the first quarter of 2018. Adjusted operating income from
G&W’s U.K./European Operations was $3.4 million in the first quarter of
2019, compared with an adjusted operating loss of $2.0 million in the
first quarter of 2018, which included operating income of $0.5 million
from ERS. The adjusted operating ratio for U.K./European Operations was
97.9% in the first quarter of 2019, compared with 101.2% in the first
quarter of 2018.(1)

Adjusted Free Cash Flow Measures (1)

Adjusted free cash flow measures for the three months ended March 31,
2019 and 2018 were as follows (in millions):

     
Three Months Ended
March 31,
2019     2018
Net cash provided by operating activities $ 103.4 $ 101.4
Allocation of adjusted cash flow to noncontrolling interest(a) (7.1 ) (9.0 )
Adjusted net cash provided by operating activities attributable to
G&W
$ 96.3 $ 92.4
Core capital expenditures(b) (59.5 ) (41.4 )
Adjusted free cash flow attributable to G&W before new business
investments and grant funded projects
$ 36.8 $ 51.0
New business investments (1.6 ) (7.5 )
Grant funded projects, net of proceeds received from outside parties(c) 2.4   (0.4 )
Adjusted free cash flow attributable to G&W $ 37.6   $ 43.1  
 
(a)   Allocation of adjusted cash flow to noncontrolling interest
(Macquarie Infrastructure and Real Assets’ (MIRA’s) 48.9% equity
ownership of G&W Australia Holdings LP (GWA) since December 1, 2016)
is calculated as 48.9% of the total of (i) cash flow provided by
operating activities of G&W’s Australian Operations, less (ii) net
purchases of property and equipment of G&W’s Australian Operations.
The timing and amount of actual distributions, if any, from GWA to
G&W and MIRA made in any given period will vary and could differ
materially from the amounts presented. No such distributions were
made for the three months ended March 31, 2019 and 2018. G&W
expressly disclaims any direct correlation between the allocation of
adjusted cash flow to noncontrolling interest and actual
distributions made in any given period.
(b) Core capital expenditures represent purchases of property and
equipment as presented on the Statement of Cash Flows less grant
proceeds from outside parties, insurance proceeds for the
replacement of assets and proceeds from disposition of property and
equipment, each of which as presented on the Statement of Cash
Flows, less new business investments and grant funded projects.
(c) Grant funded projects represent purchases of property and equipment
for projects partially or entirely funded by outside parties, net of
grant proceeds from outside parties as presented on the Statement of
Cash Flows.
 

Share Repurchase Program

During the first quarter of 2019, G&W repurchased 64,860 shares of Class
A Common Stock for $4.8 million, which resulted in a reduction of 59,095
shares in our weighted average diluted shares outstanding for the first
quarter of 2019. During the first quarter of 2018, G&W repurchased
792,921 shares of Class A Common Stock for $57.4 million, which resulted
in a reduction of 51,106 shares in our weighted average diluted shares
outstanding for the first quarter of 2018.

Conference Call and Webcast Details

As previously announced, G&W’s conference call to discuss financial
results for the first quarter of 2019 will be held on Tuesday, April 30,
2019, at 11 a.m. EDT. The dial-in number for the teleconference in the
U.S. is (800) 230-1085; outside the U.S., the dial-in number is (612)
288-0329, or the call may be accessed live over the Internet (listen
only) at www.gwrr.com/investors.
Management will be referring to a slide presentation that will also be
available at gwrr.com/investors. The webcast will be archived at www.gwrr.com/investors
until the following quarter’s earnings press release. Telephone replay
is available for 30 days beginning at 1 p.m. EDT on April 30, 2019, by
dialing (800) 475-6701 (or outside the U.S., dialing 320-365-3844). The
access code is 458667.

About G&W

G&W owns or leases 120 freight railroads organized in eight locally
managed operating regions with 8,000 employees serving 3,000 customers.

  • G&W’s six North American regions serve 41 U.S. states and four
    Canadian provinces and include 114 short line and regional freight
    railroads with more than 13,000 track-miles.
  • G&W’s Australia Region serves New South Wales, the Northern Territory
    and South Australia and operates the 1,400-mile Tarcoola-to-Darwin
    rail line. The Australia Region is 51.1% owned by G&W and 48.9% owned
    by a consortium of funds and clients managed by Macquarie
    Infrastructure and Real Assets.
  • G&W’s U.K./Europe Region includes the U.K.’s largest rail maritime
    intermodal operator and second-largest freight rail provider, as well
    as regional services in Continental Europe.

G&W subsidiaries and joint ventures also provide rail service at more
than 40 major ports, rail-ferry service between the U.S. Southeast and
Mexico, transload services, contract coal loading, and industrial
railcar switching and repair.

From time to time, we may use our website as a channel of distribution
of material company information. Financial and other material
information regarding G&W is routinely posted on and accessible at www.gwrr.com/investors.
In addition, you may automatically receive email alerts and other
information about us by enrolling your email address in the “Email
Alerts” section of www.gwrr.com/investors.
The information contained on or connected to our Internet website is not
deemed to be incorporated by reference in this press release or filed
with the United States Securities and Exchange Commission.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements regarding future
events and the future performance of Genesee & Wyoming Inc. that are
based on current expectations, estimates and projections about our
industry, management’s beliefs and assumptions made by management. Words
such as “anticipates,” “intends,” “plans,” “believes,” “could,”
“should,” “seeks,” “expects,” “will,” “estimates,” “trends,” “outlook,”
variations of these words and similar expressions are intended to
identify these forward-looking statements. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to forecast, including
the following: risks related to the operation of our railroads; severe
weather conditions and other natural occurrences, which could result in
shutdowns, derailments, railroad network and port congestion or other
substantial disruption of operations; customer demand and changes in our
operations or loss of important customers; exposure to the credit risk
of customers and counterparties; changes in commodity prices;
consummation and integration of acquisitions; economic, political and
industry conditions, including employee strikes or work stoppages;
retention and contract continuation; legislative and regulatory
developments, including changes in environmental and other laws and
regulations to which we or our customers are subject; increased
competition in relevant markets; funding needs and financing sources,
including our ability to obtain government funding for capital projects;
international complexities of operations, currency fluctuations,
finance, tax and decentralized management; challenges of managing rapid
growth, including retention and development of senior leadership;
unpredictability of fuel costs; susceptibility to and outcome of various
legal claims, lawsuits and arbitrations; increase in, or volatility
associated with, expenses related to estimated claims, self-insured
retention amounts and insurance coverage limits; consummation of new
business opportunities; decrease in revenues and/or increase in costs
and expenses; susceptibility to the risks of doing business in foreign
countries; uncertainties arising from a referendum in which voters in
the United Kingdom (U.K.) approved an exit from the European Union
(E.U.), commonly referred to as Brexit; our ability to integrate
acquired businesses successfully or to realize the expected synergies
associated with acquisitions; risks associated with our substantial
indebtedness; failure to maintain satisfactory working relationships
with partners in Australia; failure to maintain an effective system of
internal control over financial reporting as well as disclosure controls
and procedures and other risks including, but not limited to, those
noted in our 2018 Annual Report on Form 10-K and our Quarterly Reports
on Form 10-Q under “Risk Factors.” Therefore, actual results may differ
materially from those expressed or forecasted in any such
forward-looking statements. Forward-looking statements speak only as of
the date of this press release or as of the date they were made. G&W
does not undertake, and expressly disclaims, any duty to publicly update
any forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.

1.   Adjusted operating income, adjusted operating ratio, adjusted net
income attributable to G&W, adjusted diluted earnings per common
share (EPS), and the adjusted free cash flow measures of adjusted
net cash provided by operating activities attributable to G&W,
adjusted free cash flow attributable to G&W and adjusted free cash
flow attributable to G&W before new business investments and grant
funded projects are non-GAAP financial measures and are not intended
to replace financial measures calculated in accordance with GAAP.
The information required by Item 10(e) of Regulation S-K under the
Securities Act of 1933 and the Securities Exchange Act of 1934 and
Regulation G under the Securities Exchange Act of 1934, including a
reconciliation to their most directly comparable financial measures
calculated in accordance with GAAP, is included in the tables
attached to this press release.
 
2. Foreign exchange impact is calculated by comparing the prior period
results translated from local currency to U.S. dollars using current
period exchange rates to the prior period results in U.S. dollars as
reported.
 
 
GENESEE & WYOMING INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND 2018
(in thousands, except per share amounts)
(unaudited)
         
Three Months Ended
March 31,
2019 2018
OPERATING REVENUES $ 558,089 $ 574,661
OPERATING EXPENSES 478,379   487,748  
OPERATING INCOME 79,710 86,913
INTEREST INCOME 547 498
INTEREST EXPENSE (27,610 ) (25,236 )
OTHER INCOME/(LOSS), NET 419   (2,040 )
INCOME BEFORE INCOME TAXES 53,066 60,135
(PROVISION FOR)/BENEFIT FROM INCOME TAXES (14,260 ) 15,890  
NET INCOME $ 38,806 $ 76,025
LESS: NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTEREST 100   927  
NET INCOME ATTRIBUTABLE TO GENESEE & WYOMING INC. $ 38,706   $ 75,098  
BASIC EARNINGS PER COMMON SHARE ATTRIBUTABLE TO GENESEE & WYOMING
INC. COMMON STOCKHOLDERS:
$ 0.69   $ 1.21  
WEIGHTED AVERAGE SHARES – BASIC 56,368   61,918  
DILUTED EARNINGS PER COMMON SHARE ATTRIBUTABLE TO GENESEE & WYOMING
INC. COMMON STOCKHOLDERS:
$ 0.68   $ 1.19  
WEIGHTED AVERAGE SHARES – DILUTED 57,132   62,887  
 
 
GENESEE & WYOMING INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AS OF MARCH 31, 2019 AND DECEMBER 31, 2018
(in thousands)
(unaudited)
         
March 31, December 31,
2019 2018
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 70,108 $ 90,387
Accounts receivable, net 439,527 426,305
Materials and supplies 59,368 56,716
Prepaid expenses and other 66,125   54,185
Total current assets 635,128   627,593
PROPERTY AND EQUIPMENT, net 4,643,936 4,613,014
GOODWILL 1,120,212 1,115,849
INTANGIBLE ASSETS, net 1,429,602 1,430,197
DEFERRED INCOME TAX ASSETS, net 5,261 4,616
OTHER ASSETS, net(a) 547,669   77,192
Total assets $ 8,381,808   $ 7,868,461
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Current portion of long-term debt $ 26,522 $ 28,303
Accounts payable 282,917 288,070
Accrued expenses(a) 232,731   165,280
Total current liabilities 542,170   481,653
LONG-TERM DEBT, less current portion 2,391,695 2,425,235
DEFERRED INCOME TAX LIABILITIES, net 886,183 877,721
DEFERRED ITEMS – grants from outside parties 328,347 326,520
OTHER LONG-TERM LIABILITIES(a) 576,133 127,280
TOTAL EQUITY 3,657,280   3,630,052
Total liabilities and equity $ 8,381,808   $ 7,868,461
(a)   On January 1, 2019, G&W adopted Accounting Standards Update (ASU)
2016-02, Leases. The new standard requires lessees to recognize
operating leases on their balance sheet as a right-of-use asset with
a corresponding lease liability. This resulted in approximately $495
million of assets and a corresponding amount of liabilities being
recognized on G&W’s balance sheet as of March 31, 2019. Capital
leases will continue to be recognized on the balance sheet but are
now referred to as “finance” leases, as required by the new standard.
 

Contacts

Michael Williams of G&W Corporate Communications
1-203-202-8900
[email protected]

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania